Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

WuXi PharmaTech Schedules Second-Quarter 2013 Earnings Release



        WuXi PharmaTech Schedules Second-Quarter 2013 Earnings Release

PR Newswire

SHANGHAI, July 15, 2013

SHANGHAI, July 15, 2013 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE:
WX), a leading pharmaceutical, biotechnology and medical device R&D
outsourcing company with operations in China and the United States, today
announced that it will release financial results for the second quarter of
2013 after the New York Stock Exchange closes on Monday, August 12, 2013
(which will be Tuesday morning, August 13, 2013 Shanghai time). The earnings
release will be available on the investor relations section of the Company's
website at http://www.wuxiapptec.com/.

Following the earnings announcement, WuXi PharmaTech senior management will
host a conference call at 8:00 am (U.S. Eastern) / 5:00 am (U.S. Pacific) /
8:00 pm (Beijing/Shanghai/Hong Kong) on Tuesday, August 13, 2013, to discuss
the second-quarter 2013 financial results and recent business activities. The
conference call may be accessed by calling:

Australia                        1800 801 825
Belgium                          0800 784 01
Canada                           1855 842 3490
China                            4001 200 539
France                           0800 916 599
Germany                          0800 1899 399
Hong Kong                        800 905 927
Hong Kong (toll)                 +852 5808 3202
India                            000 800 100 8255
Indonesia                        00180 301 91840
Ireland                          1800 720 105
Italy                            800 875 577
Japan                            0120 271 900
Malaysia                         1800 816 107
Netherlands                      0800 0234 240
New Zealand                      0800 452 905
Singapore                        800 616 3222
South Korea                      00798 6136 1434
Sweden                           0207 968 70
Switzerland                      0800 837 001
Taiwan                           0080 161 5189
United Kingdom                   0800 015 9725
United Kingdom—London (toll)     44 (0) 20 3078 7622
United States                    1855 298 3404
United States—New York (toll)    +1 631 5142 526
Other countries (toll)           +65 6823 2299
Conference ID:                   1007691

A telephone replay will be available two hours after the call's completion at:

Australia              1800 008 585
Belgium                0800 11 797
Canada                 1866 4783 460
China                  4001 842 240
France                 0800 904 160
Germany                0800 181 3763
Hong Kong              800 966 697
India                  000 800 100 6647
Indonesia              0018 0306 12086
Ireland                1800 511 665
Italy                  800 784 706
Japan                  0066 3386 1031
Malaysia               1800 181 061
Netherlands            08000 232 153
New Zealand            0800 444 310
Singapore              800 616 2127
South Korea            00798 612 1058
Sweden                 020 792 274
Switzerland            0800 564 016
Taiwan                 00801 232 352
United Kingdom         0800 169 7301
United States          1866 846 0868
Conference ID:         1007691

A live webcast of the conference call and replay will be available in the
investor relations section of WuXi PharmaTech's website at
http://www.wuxiapptec.com/.

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device
R&D outsourcing company, with operations in China and the United States. As a
research-driven and customer-focused company, WuXi PharmaTech provides
pharmaceutical, biotechnology and medical device companies with a broad and
integrated portfolio of laboratory and manufacturing services throughout the
drug and medical device R&D process. WuXi PharmaTech's services are designed
to help its global partners in shortening the cycle and lowering the cost of
drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are
known as WuXi AppTec.

For more information, please contact:

Ronald Aldridge
Director of Investor Relations
WuXi PharmaTech (Cayman) Inc.
Tel: +1-201-585-2048
Email: Ron_Aldridge@wuxiapptec.com
Web: http://www.wuxiapptec.com

 

SOURCE WuXi PharmaTech (Cayman) Inc.

Website: http://www.wuxiapptec.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement